IBI3002 for moderate to severe asthma
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests a new drug called IBI3002 for people with moderate to severe asthma that isn't well controlled with standard inhalers. It aims to see if the drug is safe and tolerable when given multiple times.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You weigh at least 40 kg (about 88 pounds).
- You have had asthma for at least one year.
- You use a daily inhaler (with or without steroids) and your dose has been steady for at least one month.
- You have a breathing test showing your lung function is no more than 80% of normal for your age and height.
- You have high levels of inflammation markers: either a FeNO test of 25 or higher, or an eosinophil blood count of 300 or more (or 150 or more at screening).
- You have not had a life-threatening asthma attack in the last 5 years.
- You do not have active tuberculosis or other serious lung diseases like COPD.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called 610 for people with severe asthma that is not well-controlled with standard medicines. The goal is to see if adding 610 can improve asthma control and reduce flare-ups.
This trial tests a new inhaled medication called LQ036 to see if it can help people whose asthma is not well controlled with their current inhalers. Participants must have had at least one severe asthma flare-up in the last year and show signs of airway inflammation.
This study tests an investigational medicine called PF-07275315 for people with moderate-to-severe asthma that is not well controlled with current treatments. The goal is to see if it can reduce asthma attacks and improve breathing.
This study tests an investigational drug (called JNJ-95597528) taken as a pill, to see if it can reduce asthma attacks and improve control in people with moderate to severe asthma that isn't well controlled by current inhalers. It may be a new option to help reduce airway inflammation and improve your breathing.
This study tests an investigational medicine called tilrekimig for people with severe asthma that isn't well controlled. It aims to reduce asthma attacks and improve breathing.
This trial tests an investigational drug called TQC2731 for people with severe asthma that is not well controlled despite high-dose inhaled steroids. The study aims to see if this treatment can reduce asthma attacks.
Hear when a new Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.